Key Drivers
- Margin Resilience
- Strong Cash Flow
- Elevated Leverage
AIAI Summary
DGX now looks more constructive as re-accelerating core testing demand is lifting guidance and supporting a higher dividend, but at ~23–24x earnings the stock already prices in stability, leaving returns dependent on continued execution while leverage and reimbursement pressure remain the main downside risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Resilience
- •Strong Cash Flow
- •Elevated Leverage
DGX has resilient profitability, strong free cash flow, and improving liquidity, but its elevated leverage and full valuation make the stock more dependent on continued execution than on cheap pricing.
Price Behavior
Key Price Behavior Insights:
- •Breakout surge
- •Higher-highs pattern
- •Cooling momentum
DGX remains in a constructive uptrend over the last month after breaking out from the low-$210s into the upper-$220s, but momentum has cooled with $231-$234 as key support and $238-$239 as near-term resistance.
Sharp breakout from the low-$210s into the upper-$220s, followed by a pullback from about $238.50
Sentiment & News
Key News Insights:
- •Strong Q2 beat
- •Demand expansion
- •Margin pressure
Quest Diagnostics delivered a strong Q2 beat-and-raise on broad testing demand and partnerships, and despite valuation and cost concerns, the stock has kept its post-earnings momentum while supporting income with a new dividend.
The news is modestly positive for DGX, as solid growth and dividend support outweigh near-term valuation and cost risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings